Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pharma Mar, S.A. (PHMMF)

Other OTC - Other OTC Delayed Price. Currency in USD
68.500.00 (0.00%)
At close: 02:50PM EST
Advertisement

Pharma Mar, S.A.

Avenida de los Reyes, 1
Pol. Industrial La Mina – Norte Colmenar Viejo
Madrid 28770
Spain
34 91 846 60 00
https://www.pharmamar.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees477

Key Executives

NameTitlePayExercisedYear Born
Mr. Jose Maria Fernandez Sousa-FaroFounder, Exec. Chairman, CEO & Pres290.64kN/AN/A
Mr. Pedro Francisco Fernandez PuentesExec. Vice-Chairman122.58kN/AN/A
Mr. Juan Carlos-Torres CarreteroFounderN/AN/A1949
Ms. María Luisa de Francia CaballeroChief Financial OfficerN/AN/AN/A
Ms. Elena Calleja CrespoDirector of Fin. & Admin.N/AN/AN/A
Mr. José Luis Moreno Martinez-LosaDirector of Capital Markets & Investor RelationsN/AN/AN/A
Mr. Juan Gomez PulidoGen. Counsel & Sec. of the Board of DirectorsN/AN/AN/A
Ms. Sandra Llamera SanchezGlobal Compliance HeadN/AN/AN/A
Ms. Lara VadilloCommunication DirectorN/AN/AN/A
Mr. Juan NoguesDirector of International Marketing & SalesN/AN/AN/A
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Corporate Governance

Pharma Mar, S.A.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement